Biotech Company Chai Discovery, Supported by OpenAI, Raises $130 Million in Funding with a Valuation of $1.3 Billion
Chai Discovery completes $130 million in Series B funding, with a valuation of $1.3 billion, led by General Catalyst and Oak HC/FT, with participation from several renowned investment institutions. The company's total funding exceeds $225 million, focusing on drug discovery. The industry is gradually recognizing the potential of artificial intelligence in drug development.